MarketPulse

daridorexant

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Nxera Pharma

Nxera Pharma Posts Strong Q1 2026 as Spinoff Centessa Fetches $7.8B Lilly Deal

Nxera Pharma reported JPY 11.3B Q1 revenue driven by R&D milestones. Spinoff Centessa agreed to $7.8B acquisition by Eli Lilly.
ABBVLLYCNTANBIXrevenue growthdrug discovery
GlobeNewswire Inc.GlobeNewswire Inc.··Nxera Pharma Co., Ltd.

Nxera Pharma Pursues South Korea Insomnia Market With Daridorexant Filing

Nxera Pharma seeks South Korean approval for insomnia drug daridorexant, already marketed globally, with expected 2027 regulatory decision.
SGIOYPhase 3 trialregulatory approval